Trial Profile
Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs CK 0801 (Primary)
- Indications Aplastic anaemia; Bone marrow disorders; Myelodysplastic syndromes; Myelofibrosis
- Focus Adverse reactions
- Sponsors Cellenkos
- 05 Feb 2024 Planned End Date changed from 30 Jan 2024 to 30 May 2024.
- 05 Feb 2024 Planned primary completion date changed from 25 Jan 2024 to 25 May 2024.
- 28 Aug 2023 Planned End Date changed from 30 Jan 2023 to 30 Jan 2024.